The Pharmaceutical Research and Manufacturers of America said Wednesday it had filed a complaint in the U.S. District Court for the District of Columbia challenging the administration’s most-favored-nation pilot in Medicare Part B. The trade group’s assertion is that the pilot exceeds Medicare’s statutory authority. The program, known as GLOBE, is intended to test tying Medicare prices to those paid in peer countries.
The practical stakes of this particular pilot are narrower than the legal principle. According to STAT’s reporting, GLOBE is not expected to have much direct impact because the administration exempted all but a handful of companies in exchange for their agreement to voluntary deals charging Medicaid most-favored-nation prices. The lawsuit is therefore as much about the precedent as the pilot: if MFN pricing in Part B survives statutory challenge, the same mechanism can be pointed at a wider set of drugs.
For the sector, the filing crystallizes a risk that has been building all year. Pricing policy is moving on two independent tracks: negotiation and demonstration authority on one side, and tariffs on the other. The Section 232 tariff on imported patented drugs took effect at the end of September. Companies now have to model not just what they can charge, but what it costs to bring product across the border, and PhRMA is litigating the price side while its smaller members absorb the tariff side.